Scarica l'app Stockscreener
17.04
0.83%
0.14
Dopo l'orario di chiusura:
17.04
Precedente Chiudi:
$16.90
Aprire:
$17.19
Volume 24 ore:
115.46K
Relative Volume:
0.61
Capitalizzazione di mercato:
$578.52M
Reddito:
$99.99M
Utile/perdita netta:
$-21.47M
Rapporto P/E:
-25.83
EPS:
-0.6597
Flusso di cassa netto:
$-11.34M
1 W Prestazione:
+0.89%
1M Prestazione:
+16.31%
6M Prestazione:
+31.28%
1 anno Prestazione:
+47.79%
Intervallo 1D:
$16.69
$17.26
Intervallo di 1 settimana:
$15.98
$17.85
Portata 52W:
$7.5625
$18.98
Neuropace Inc Stock (NPCE) Company Profile
Nome
Neuropace Inc
Settore
Industria
Telefono
(650) 237-2700
Indirizzo
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
17.04 | 573.76M | 99.99M | -21.47M | -11.34M | -0.6597 |
ABT
Abbott Laboratories
|
87.17 | 152.48B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
295.25 | 111.40B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
77.79 | 100.53B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.98 | 84.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.91 | 48.04B | 6.30B | 1.07B | 1.34B | 1.8406 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-28 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-21 | Iniziato | UBS | Buy |
| 2024-03-14 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Iniziato | Leerink Partners | Outperform |
| 2023-11-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Iniziato | Lake Street | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-01-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Iniziato | Robert W. Baird | Outperform |
| 2021-05-17 | Iniziato | JP Morgan | Overweight |
| 2021-05-17 | Iniziato | Morgan Stanley | Overweight |
| 2021-05-17 | Iniziato | SVB Leerink | Outperform |
| 2021-05-17 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Neuropace Inc Borsa (NPCE) Ultime notizie
Here's why you should add NeuroPace stock to your portfolio now - MSN
NeuroPace (NPCE) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Liquidity Mapping Around (NPCE) Price Events - Stock Traders Daily
RNS System delivers life changing outcomes in 3 year post approval study, NeuroPace Inc reveals - Traders Union
NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026 - Business Wire
NeuroPace Inc warns less than 5 percent seizure reduction when medications fail twice - Traders Union
NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026 - BioSpace
NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study Results in Neurology and NAUTILUS Presentation at AAN 2026 - Investing News Network
NPCE Neuropace posts far narrower than expected Q4 2025 loss even as shares dip slightly today.Institutional Grade Picks - Newser
Wall Street analysts see a 41.29% upside in NeuroPace (NPCE): Can the stock really move this high? - MSN
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
NPCE Neuropace posts smaller than expected Q4 2025 loss, sending shares 2.38 percent higher in today’s trading. - Cổng thông tin điện tử tỉnh Lào Cai
Why (NPCE) Price Action Is Critical for Tactical Trading - Stock Traders Daily
NeuroPace (NASDAQ: NPCE) plans 2026 virtual vote on board and auditor - Stock Titan
NeuroPace Inc introduces RNS System as alternative for patients unresponsive to epilepsy medications - Traders Union
NeuroPace Inc reports 77 percent drop in GTCs with NAUTILUS trial data - Traders Union
NeuroPace Inc unveils NAUTILUS Study results at AAN Annual Meeting - Traders Union
NeuroPace Inc unveils NAUTILUS Study findings on neuromodulation for drug-resistant IGE - Traders Union
Neuropace, Inc. (NPCE) Stock Analysis: A Healthcare Innovator with a Promising 28% Potential Upside - DirectorsTalk Interviews
NeuroPace (NPCE) up 0.9% since last earnings report: Can it continue? - MSN
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference - marketscreener.com
Day Trade: Is NeuroPace Inc a stock for growth or value investorsMarket Risk Report & Daily Growth Stock Investment Tips - baoquankhu1.vn
Understanding Momentum Shifts in (NPCE) - Stock Traders Daily
Forecast Cut: Will NeuroPace Inc stock benefit from M AMarket Growth Report & Capital Protection Trade Alerts - baoquankhu1.vn
Aug EndMonth: Should I hold or sell NeuroPace Inc nowWeekly Risk Summary & Weekly Stock Performance Updates - baoquankhu1.vn
Neuropace, Inc. (NPCE) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Quarterly Recap: Whats the analyst consensus on NeuroPace IncM&A Rumor & Weekly High Return Stock Forecasts - baoquankhu1.vn
Neuropace, Inc. (NPCE) Stock Price Prediction for 2026, 2030-2040 - Traders Union
NeuroPace, Inc. (NPCE) stock price, news, quote and history - Yahoo Finance UK
NeuroPace Earnings Call Highlights Growth And AI Push - The Globe and Mail
Here’s why investing in NeuroPace shares could be a smart addition to your portfolio at this time - Bitget
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now - Zacks Investment Research
Wall Street Analysts See a 41.29% Upside in NeuroPace (NPCE): Can the Stock Really Move This High? - sharewise.com
NeuroPace (NPCE) Up 0.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
How Shifting Margin Assumptions Are Rewriting The NeuroPace (NPCE) Investment Narrative - Yahoo Finance
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Neuropace Inc Azioni (NPCE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.41%
0.93%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):